隶属于 EMORY UNIVERSITY
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1854
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Cocrystal Pharma has completed dosing the last participant in a placebo-controlled Phase 1b human challenge study of CDI-988, an oral norovirus protease inhibitor, at Emory University School of Medicine. - The trial uses the well-characterized Snow Mountain Virus strain and enrolled 40 subjects in isolated units, with symptoms and viral load as clear endpoints. - CDI-988 holds FDA fast track designation for norovirus treatment and prophylaxis, with preliminary results expected in late 2026 or early 2027. - Norovirus causes an estimated 685 million illnesses and $60 billion in global costs annually, yet no specific antiviral treatment currently exists.
- Researchers identified anti-Müllerian hormone (AMH) as a blood biomarker that more accurately predicts chemotherapy benefit than age or menopausal status in women under 55 with hormone receptor-positive, HER2-negative breast cancer. - In the RxPONDER trial analysis of 1,556 women, those with AMH levels ≥10 pg/mL saw a 54% reduction in invasive disease recurrence risk with chemotherapy (HR=0.46), while those below the threshold derived no benefit. - Approximately one in five premenopausal women had AMH levels low enough to potentially safely forgo chemotherapy and its associated toxicities. - The findings suggest measuring ovarian reserve via ultrasensitive AMH and inhibin B assays should become part of shared decision-making before adjuvant therapy selection.
- CellCentric has initiated DOMMINO-1, a pivotal Phase 2 trial evaluating inobrodib 20 mg combined with pomalidomide and dexamethasone in heavily pretreated relapsed or refractory multiple myeloma patients. - The combination previously demonstrated a 60% objective response rate and response rates at least 2x greater than alternatives in pomalidomide-refractory patients following bispecific or anti-BCMA therapy. - The open-label, single-arm study will enroll 100 patients across UK and US sites, targeting patients who have exhausted multiple treatment options including bispecific antibodies. - Inobrodib represents a first-in-class oral p300/CBP inhibitor that could provide a transformative all-oral treatment option for patients with limited therapeutic alternatives.
- Cocrystal Pharma received IRB approval from Emory University School of Medicine to initiate a Phase 1b human challenge study with CDI-988, the first oral antiviral drug candidate for norovirus prevention and treatment. - The randomized, double-blind, placebo-controlled study will enroll up to 40 healthy subjects ages 18-49 and evaluate CDI-988's efficacy in reducing clinical symptoms and viral shedding. - CDI-988 targets the highly conserved 3CL protease region across all norovirus strains and addresses a significant unmet medical need, as no approved treatments or vaccines currently exist for norovirus infections. - Norovirus causes approximately 700 million cases globally and 21 million cases annually in the U.S., resulting in substantial healthcare burden and economic costs exceeding $60 billion worldwide.
- Only one in three patients visiting emergency departments for sickle cell pain crises received guideline-recommended opioid medications within the first hour, with adult patients, females, and those with public insurance experiencing worse care. - Preliminary results from pediatric gene therapy trials show 100% success rates, with all children aged 5-11 meeting primary endpoints for transfusion independence or freedom from vaso-occlusive crises. - Long-term transplant data from over 1,000 patients demonstrates 90% survival rates at seven years, with 86% remaining free from sickle cell disease symptoms. - Real-world commercial implementation of gene therapies shows median treatment timelines of 7.9-9.8 months from enrollment to infusion, with manufacturing capacity and insurance approvals as key factors.
- Rutgers Health, Emory University, and Stevens Institute of Technology received a three-year $2.8 million NIH grant to develop an advanced neurostimulation device for drug-resistant epilepsy patients. - The new Epileptic-Network Closed-loop Stimulation Device (enCLS) aims to improve upon existing technology that currently eliminates seizures in only 15-20% of patients. - The interdisciplinary team plans to create a device with enhanced seizure prediction algorithms and broader brain stimulation capabilities, targeting market introduction within five years. - Emory's contribution includes clinical validation using data from over 60 patients with existing responsive neurostimulation implants to refine the new technology.
- Over 75% of dementia patients are unaware of their diagnosis despite having access to primary care, with higher unawareness rates among Mexican-Americans (85%) compared to white patients (68%). - A separate study found that 75% of low-income seniors at community health centers had undiagnosed cognitive issues, with Black patients more than twice as likely as whites to have unrecognized cognitive impairment. - Medical experts emphasize that timely dementia diagnosis is crucial for proper treatment, support services, and potential interventions that could slow disease progression.
- Analysis published in Cancer projects 28.4 million new cancer cases worldwide by 2040, with low-income countries facing disproportionately higher mortality rates despite global treatment advances. - Research reveals significant economic barriers in cancer care, with low-income nations paying more for essential cancer drugs while spending less of their GDP on overall cancer treatment. - Study proposes solutions including price discrimination, international funding, and improved screening methods to address growing disparities in global cancer care access.
- Early biomarker testing is essential for identifying driver mutations in early-stage NSCLC patients, enabling physicians to select optimal targeted therapies versus immunotherapy approaches. - Multidisciplinary tumor boards and team approaches are crucial for aligning treatment decisions and streamlining patient care in perioperative NSCLC management. - Implementation of reflex testing and early medical oncology consultation can help overcome barriers like biomarker test turnaround times and ensure timely treatment initiation.
- The American Heart Association's new scientific statement highlights lipoprotein apheresis as an underutilized treatment that can reduce LDL-C and Lp(a) levels by 65-85% in a single session for familial hypercholesterolemia patients. - Despite approximately 11,000-15,000 Americans qualifying for lipoprotein apheresis treatment, fewer than 400 currently receive it, highlighting significant access barriers and awareness gaps. - Clinical studies demonstrate lipoprotein apheresis can reduce major adverse cardiovascular events by 50-85%, with annual treatment costs ranging from $50,000-$150,000, significantly lower than alternative therapies.
